Enoxaparin sodium

Generic Name: Enoxaparin sodium

Brand Names: Lovenox, Inhixa

Drug Type: Small Molecule

CAS Number: 9005-49-6

Unique Ingredient Identifier: E47C0NF7LV

Background: Enoxaparin is a common low-molecular-weight heparin (LMWH) used in the prevention and management of various thromboembolic disorders. Initially approved by the FDA in 1993, it is administered by a subcutaneous or intravenous injection and marketed by several pharmaceutical companies. Enoxaparin markedly reduces the incidence of venous thromboembolism in hospitalized patients when compared to unfractionated heparin, without increasing the risk of serious bleeding.

Indication: Enoxaparin is indicated for the prevention of ischemic complications in unstable angina and in non Q-wave myocardial infarction; it is indicated in conjunction with percutaneous intervention and/or other treatment for the management of acute ST elevation myocardial infarction.

Enoxaparin is also indicated in the prophylaxis of DVT in abdominal surgery, hip replacement, knee replacement, or medical patients with severely restricted mobility during acute illness. Additionally, enoxaparin is indicated for the inpatient treatment of DVT with or without pulmonary embolism and the treatment of outpatient DVT without pulmonary embolism.

Associated Conditions: Acute Coronary Syndrome (ACS), Acute Myocardial Infarction With ST Segment Elevation, Deep Vein Thrombosis, Ischemic complications caused by non-q wave myocardial infarction, Ischemic complications caused by unstable angina

Associated Therapies: Percutaneous Coronary Intervention (PCI)

Clinical Trials

Thromboprophylaxis and Bariatric Surgery

Phase 4

Conditions: Thromboembolism

First Posted Date: 2007-03-08

Last Posted Date: 2012-07-02

Lead Sponsor: University Hospital, Strasbourg, France

Target Recruit Count: 300

Registration Number: NCT00444652

Locations: 🇫🇷
Département d'Anesthésiologie Hôpital Civil, Strasbourg, Alsace, France
🇫🇷
Clinique de l'Orangerie, Strasbourg, Alsace, France
🇫🇷
Laboratoire d'hémostase Hôpital de Hautepierre, Strasbourg, Alsace, France

and more 7 locations

Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep Vein Thrombosis - The EINSTEIN DVT Study

Phase 3

Completed

Conditions: Venous Thrombosis

Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939)
Drug: Enoxaparin followed by VKA

First Posted Date: 2007-02-26

Last Posted Date: 2014-02-27

Lead Sponsor: Bayer

Target Recruit Count: 3449

Registration Number: NCT00440193

Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Pulmonary Embolism - The EINSTEIN PE Study

Phase 3

Completed

Conditions: Pulmonary Embolism

Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939)
Drug: Enoxaparin overlapping with and followed by VKA

First Posted Date: 2007-02-26

Last Posted Date: 2014-02-27

Lead Sponsor: Bayer

Target Recruit Count: 4833

Registration Number: NCT00439777

Enoxaparin Versus Unfractionated Heparin in PCI

Phase 4

Completed

Conditions: Coronary Artery Disease

First Posted Date: 2007-02-26

Last Posted Date: 2007-02-26

Lead Sponsor: Triemli Hospital

Target Recruit Count: 2100

Registration Number: NCT00439855

Locations: 🇨🇭
Division of Cardiology Triemli Hospital Zurich, Zurich, Switzerland

Docetaxel and Liposomal Doxorubicin Chemotherapy With Enoxaparin in Patients With Advanced Pancreatic Cancer

Phase 2

Terminated

Conditions: Pancreatic Cancer

Interventions: Drug: Docetaxel
Drug: Liposomal Doxorubicin
Drug: Enoxaparin

First Posted Date: 2007-01-24

Last Posted Date: 2017-12-29

Lead Sponsor: University of Iowa

Target Recruit Count: 2

Registration Number: NCT00426127

Locations: 🇺🇸
University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States

Study of an Investigational Drug for the Prevention of Thrombosis-related Events Following Hip Replacement Surgery (ADVANCE-3)

Phase 3

Completed

Conditions: Deep Vein Thrombosis
Pulmonary Embolism

Interventions: Drug: Apixaban
Drug: Enoxaparin
Drug: Enoxaparin-matching placebo
Drug: Apixaban-matching placebo

First Posted Date: 2007-01-18

Last Posted Date: 2014-05-14

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 5407

Registration Number: NCT00423319

Locations: 🇺🇸
Shrock Orthopedic Research, Ft. Lauderdale, Florida, United States
🇺🇸
Orthoarkansas, P.A., Little Rock, Arkansas, United States
🇺🇸
Pab Clinical Research, Brandon, Florida, United States

and more 17 locations